Literature DB >> 27845850

CT-Guided Percutaneous Lung Biopsies in Patients With Suspicion for Infection May Yield Clinically Useful Information.

Brian M Haas1, Joshua D Clayton1, Brett M Elicker1, Karen G Ordovas1, David M Naeger1.   

Abstract

OBJECTIVE: The objective of our study was to assess the frequency and time frame with which CT-guided lung biopsies for suspected infection yield information that can affect patient management.
MATERIALS AND METHODS: All CT-guided lung biopsies over a 68-month period performed for the purpose of diagnosing a suspected infection were reviewed to determine the proportion that yielded information affecting patient management. Patients were included if infection was the only consideration causing the pulmonary lesion in question.
RESULTS: Twenty-one biopsies were performed to identify a specific organism causing infection in patients with suspected infection; all patients were receiving antibiotics, 20 (95%) were immunocompromised, and 15 (71%) had undergone a prior bronchoscopy. Material collected from the biopsy provided a diagnosis in nine (43%) patients, whereas the biopsy results were nondiagnostic in the remaining 12 (57%). Of the nine patients for whom the biopsy yielded a diagnosis, eight biopsies revealed the species causing an infection (38%) and one biopsy (5%) detected posttransplant lymphoproliferative disease. Of the nine diagnoses, management was changed as a result of the biopsy in six patients (29% of all patients). The organisms identified by CT-guided lung biopsy in eight patients were fungi of the order Mucorales (i.e., mucormycosis) (n = 3), Aspergillus (n = 3), Pseudomonas (n = 1), and Nocardia (n = 1). The mean elapsed time between biopsy and pathologic diagnosis was 4 days (median, 3 days). There was no association between prior bronchoscopy and nondiagnostic biopsy results.
CONCLUSION: CT-guided lung biopsies in patients with a high pretest suspicion for infection result in information sufficient to change patient management in 29% of patients. Organisms identified in these patients were most frequently fungi.

Entities:  

Keywords:  immunocompromise; lung biopsy; pneumonia; pulmonary consolidations

Mesh:

Year:  2016        PMID: 27845850     DOI: 10.2214/AJR.16.16255

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  CT-guided Core-Needle Biopsy of the Lung Is Safe and More Effective than Fine-Needle Aspiration Biopsy in Patients with Hematologic Malignancies.

Authors:  Gaurav V Watane; Mark M Hammer; Maria F Barile
Journal:  Radiol Cardiothorac Imaging       Date:  2019-12-19

2.  Usefulness of CT-Guided Percutaneous Transthoracic Needle Lung Biopsies in Patients with Suspected Pulmonary Infection.

Authors:  Junghoon Kim; Kyung Hee Lee; Jun Yeun Cho; Jihang Kim; Yoon Joo Shin; Kyung Won Lee
Journal:  Korean J Radiol       Date:  2020-05       Impact factor: 3.500

Review 3.  Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.

Authors:  Ayushi Sharma; Anjana Goel
Journal:  Folia Microbiol (Praha)       Date:  2022-02-26       Impact factor: 2.629

Review 4.  Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Authors:  Valliappan Muthu; Ritesh Agarwal; Atul Patel; Soundappan Kathirvel; Ooriapadickal Cherian Abraham; Ashutosh Nath Aggarwal; Amanjit Bal; Ashu Seith Bhalla; Prashant N Chhajed; Dhruva Chaudhry; Mandeep Garg; Randeep Guleria; Ram Gopal Krishnan; Arvind Kumar; Uma Maheshwari; Ravindra Mehta; Anant Mohan; Alok Nath; Dharmesh Patel; Shivaprakash Mandya Rudramurthy; Puneet Saxena; Nandini Sethuraman; Tanu Singhal; Rajeev Soman; Balamugesh Thangakunam; George M Varghese; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2022-04-04       Impact factor: 71.421

5.  Supplementary benefits of CT-guided transthoracic lung aspiration biopsy for core needle biopsy.

Authors:  Jia-Huan He; Jia-Xing Ruan; Ying Lei; Zhi-Dan Hua; Xiang Chen; Da Huang; Cheng-Shui Chen; Xu-Ru Jin
Journal:  Front Microbiol       Date:  2022-09-14       Impact factor: 6.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.